Results Of Itrack Global Data Registry To Support The Role Of Canaloplasty For Treatment Of Glaucoma
Published 2025 - 43rd Congress of the ESCRS
Reference: FP22.03 | Type: Free paper | DOI: 10.82333/4h9z-xc26
Authors: Marlies Ullrich* 1 , Hannah Ivellio-Vellin 1 , Caroline Pilwachs 1 , Álvaro Fernández-Vega Sanz 2 , Marie-José Tassignon 3 , Domagoj Ivastinovic 4 , Oliver Findl 1
1Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital,Vienna,Austria, 2Instituto Oftalmológico Fernández-Vega,Oviedo,Spain, 3Department of Ophthalmology, Antwerp University Hospital, University of Antwerp,Antwerp,Belgium, 4Department of Ophthalmology, Medical University of Graz,Graz,Austria
Purpose
The iTrack Global Data Registry (iTGDR) was established to collect comprehensive real-world data on the efficacy and safety of canaloplasty. Key outcomes include intraocular pressure (IOP) reduction, medication use, endothelial cell count, adverse events, and procedure-specific parameters.
Setting
Multicenter cloud-based database of real-world study conducted in the USA, Canada, Europe, Asia, and Australia.
Methods
Prospective data were collected, including patients with primary and secondary open-angle glaucoma undergoing canaloplasty. The safety population encompassed all enrolled eyes, while the effectiveness population included eyes with at least 12 months of follow-up. Outcomes were assessed at baseline and postop (last available follow-up). Success was defined as an IOP reduction of ≥20% from baseline without an increase in medication use, or IOP ≤18 mmHg without medications.
Results
The safety population included 465 eyes of 353 patients up to November 2024: intraoperative complications occurred in 0.6% of cases (3 eyes), and postoperative complications in 3.4% of cases (16 eyes). The effectiveness population consisted of 257 eyes with mean postop follow-up of 21.8±8 months. Mean baseline IOP and medication use were 17.4±5.4 mmHg and 2.1±1.2, respectively, and were significantly reduced to 14.2±4.0 mmHg and 1.3±1.4 medications (p<0.001). Medication-free eyes increased from 8.2% at baseline to 44.7% postoperatively. Complete success was achieved in 62.3% of eyes at postop.
Conclusions
Canaloplasty performed via an ab-interno approach effectively reduced IOP and medication use in patients with primary and secondary open-angle glaucoma. The iTGDR provides valuable real-world evidence on the clinical effectiveness of canaloplasty, supporting evidence-based decision-making for surgeons aiming to improve outcomes in glaucoma treatment.